Esophageal Cancer Clinical Trials

260 recruitingLast updated: June 17, 2026

There are 260 actively recruiting esophageal cancer clinical trials across 41 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Esophageal Cancer Trials at a Glance

260 actively recruiting trials for esophageal cancer are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 2 with 77 trials, with the heaviest enrollment activity in Houston, Nashville, and New York. Lead sponsors running esophageal cancer studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, and Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Browse esophageal cancer trials by phase

Treatments under study

About Esophageal Cancer Clinical Trials

Looking for clinical trials for Esophageal Cancer? There are currently 196 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 260 trials

Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Not Applicable

The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy

Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences300 enrolled1 locationNCT07187154
Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting
Phase 1

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Breast CancerColorectal, CancerEsophageal Cancer+3 more
Immunome, Inc.175 enrolled1 locationNCT07578571
Recruiting
Not Applicable

FAZA PETMRI Gastro-Oesophageal Study

Metastasized Gastro-Oesophageal Cancer
University Health Network, Toronto40 enrolled1 locationNCT04560036
Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 2

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.

Gynecologic CancersEsophageal CancerGastrointestinal Cancers
John Waters50 enrolled1 locationNCT07039526
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Perspective Therapeutics112 enrolled8 locationsNCT06710756
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled746 locationsNCT05334069
Recruiting
Phase 2

BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Gastroesophageal Cancer (GC)Pancreatic Cancer, Adult
Barbara Malene Fischer90 enrolled1 locationNCT07629609
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled14 locationsNCT07217704
Recruiting
Not Applicable

Liquid Biopsies in Esophageal Cancer

Esophageal Cancer
Universitaire Ziekenhuizen KU Leuven248 enrolled4 locationsNCT05704530
Recruiting
Phase 2

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital120 enrolled1 locationNCT07162506
Recruiting
Phase 2

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Phase 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled269 locationsNCT07431281